Revvity, Inc. Hits New 52-Week High at USD 126.86

Revvity, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 126.86 on August 26, 2026. This achievement marks a notable increase from its 52-week low of USD 81.23, reflecting a robust performance over the past year. In terms of financial metrics, Revvity has demonstrated a one-year performance of 15.6%, which, while slightly trailing the S&P 500's 18.71%, indicates a solid growth trajectory within its industry. The company boasts a market capitalization of USD 9,380 million and a price-to-earnings (P/E) ratio of 30.00, suggesting a premium valuation relative to its earnings. Additionally, Revvity offers a dividend yield of 0.35% and maintains a debt-to-equity ratio of 0.32, highlighting a conservative approach to leverage. The return on equity stands at 4.36%, and the price-to-book ratio is recorded at 1.29, further illustrating the company's financial health. This recent price movement underscores Revvity's position in the market as it continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry.